Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2019-01-15 Legal Proceedings Report
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Medical AB ger uppdatering gällande möten med regulatoriska myndigheter för imlifidase vid njurtransplantation
Legal Proceedings Report Classification · 99% confidence The document is a press release dated January 15, 2019, from Hansa Medical AB, providing an update on discussions with regulatory authorities (EMA and FDA) regarding their drug imlifidase for kidney transplantation. It details progress, timelines for submission (Q1 2019 for EMA), and next steps with the FDA. It also includes background information on the drug and the medical need. This type of communication, focusing on regulatory progress and clinical development updates outside of a formal quarterly/annual report or earnings release, fits best under a general regulatory announcement or investor relations update. Since it is not a formal financial report (10-K, IR, ER, MRQ) nor a specific announcement like a dividend (DIV) or management change (MANG), and it is a direct update on regulatory/clinical status, it is classified as a general Regulatory Filing (RNS) as it serves as a broad regulatory/investor communication. It is not an Earnings Release (ER) as it focuses on regulatory dialogue, not financial results. It is not an Investor Presentation (IP) as it is a text-based press release, not a slide deck. It is not a Legal Report (LTR) as it discusses regulatory dialogue, not litigation. RNS is the most appropriate fallback for specific operational/regulatory updates that don't fit other categories.
2019-01-15 Swedish
Hansa Medical AB under namnbyte till Hansa Biopharma AB
Regulatory Filings Classification · 95% confidence The document is a short press release from Hansa Medical AB announcing a name change to Hansa Biopharma AB, effective after approval by the Swedish Companies Registration Office (Bolagsverket). It also mentions the change in the stock ticker from 'HMED' to 'HNSA'. This type of announcement, which details a structural or administrative change (like a name change or ticker change) that is not a standard financial report (10-K, IR, ER) or a specific transaction (DIV, POS), fits best under the general regulatory announcement category, as it is a material event disclosed to the market. Since there is no specific category for 'Name Change Announcement', and it is a formal regulatory disclosure, the most appropriate fallback is 'Regulatory Filings' (RNS). The document length is short (1811 chars), but it is the primary content, not an announcement *about* another report, so RPA is less suitable than RNS for this type of corporate action disclosure.
2018-12-20 Swedish
Hansa Medical AB to change name to Hansa Biopharma AB
Regulatory Filings Classification · 99% confidence The document announces that Hansa Medical AB has officially changed its name to Hansa Biopharma AB following resolutions approved at an Extraordinary General Meeting (EGM) and subsequent approval by the Swedish Companies Registration Office ('Bolagsverket'). It also notes the stock ticker change. This type of announcement, dealing with a fundamental corporate identity change (name change) that was previously voted on by shareholders, does not fit neatly into standard financial reporting categories like 10-K, ER, or IR. It is a significant corporate action announcement. Since there is no specific code for a 'Name Change Announcement', and it is a formal regulatory update regarding corporate structure/identity, it best fits the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous official announcements not covered elsewhere. It is not a Director's Dealing (DIRS), Capital Change (SHA), or Voting Result (DVA), although it relates to an EGM.
2018-12-20 English
Kommuniké från extra bolagsstämma i Hansa Medical AB (publ)
AGM Information Classification · 99% confidence The document is titled "Kommuniké från extra bolagsstämma i Hansa Medical AB (publ)" (Communication from the Extraordinary General Meeting in Hansa Medical AB (publ)). It explicitly states that decisions were made at the EGM, specifically changing the company's name (firma) to Hansa Biopharma AB. Since the document reports the decisions made at a general meeting, it relates to shareholder voting outcomes or the meeting itself. While it's not a formal DVA (Declaration of Voting Results), it is a direct communication about the proceedings and outcomes of a general meeting. Given the options, 'AGM-R' (AGM Information) is the closest fit for material related to a General Meeting, even though this is an 'Extra' (Extraordinary) meeting. It is a formal announcement regarding the meeting's outcome, which aligns best with AGM-R compared to other specific categories like ER, 10-K, or CT.
2018-12-11 Swedish
Bulletin from the Extraordinary General Meeting of Hansa Medical AB (publ)
AGM Information Classification · 99% confidence The document is titled "Bulletin from the Extraordinary General Meeting of Hansa Medical AB (publ)" and details resolutions passed at this meeting, specifically the change of the company name. This type of announcement, detailing outcomes of a shareholder meeting, falls under the scope of AGM-related materials, even though it is an Extraordinary General Meeting (EGM) rather than the Annual General Meeting (AGM). Since the provided definitions include 'AGM Information (Code: AGM-R)' for AGM materials, and there is no specific code for EGM resolutions, AGM-R is the most appropriate fit for general shareholder meeting outcome announcements. The length is short, but the content is the resolution itself, not an announcement *about* a resolution being published, making AGM-R better than RPA or RNS.
2018-12-11 English
Hansa Medical AB Announces Increase in Number of Shares and Votes
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces an 'Increase in Number of Shares and Votes' resulting from a previously resolved 'share issue of 1,776,765 ordinary shares'. It details the resulting total number of outstanding shares and the registered share capital. This action directly relates to changes in the company's capital structure, specifically the issuance of new shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not a general regulatory filing (RNS) because it is highly specific to a capital event, nor is it a financing update (CAP) which usually implies debt or fundraising rounds, although there is overlap. The core event is the share issuance itself.
2018-11-30 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.